

Kenichiro Uemura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7182868/publications.pdf>

Version: 2024-02-01

91
papers

2,068
citations

201674

27
h-index

254184

43
g-index

92
all docs

92
docs citations

92
times ranked

2746
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 623-632.	1.9	6
2	Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis of pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2022, 22, 414-420.	1.1	6
3	Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study. <i>Trials</i> , 2022, 23, 135.	1.6	1
4	Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study). <i>Trials</i> , 2022, 23, 119.	1.6	6
5	Optimal lymph-node dissection for pancreatic tail cancer. <i>Surgery Today</i> , 2022, 52, 1307-1312.	1.5	4
6	Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pancreatic cancer. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 635-641.	0.8	3
7	Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer. <i>Pancreatology</i> , 2022, 22, 258-263.	1.1	1
8	Impact of disintegrin and metalloproteinase domain-containing protein 12 on pancreatic ductal adenocarcinoma treated with surgical resection and perioperative chemotherapy. <i>Pancreatology</i> , 2022, , .	1.1	0
9	Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. <i>Pancreatology</i> , 2022, 22, 583-589.	1.1	3
10	Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using inverse probability of treatment weighting. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 911-921.	2.6	2
11	Clinicopathological features of gastric cancer after pancreaticoduodenectomy: reporting of three institutional cases and review of the global literature. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2259-2271.	1.9	1
12	Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3135-3144.	1.5	15
13	Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 679-689.	1.9	3
14	Changes in motor function and quality of life after surgery in patients with pancreatic cancer. <i>European Journal of Cancer Care</i> , 2021, 30, e13368.	1.5	5
15	ASO Author Reflections: Clinical Implications of Circulating Tumor DNA in Pancreatic Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 3145-3146.	1.5	0
16	Tension Pneumoperitoneum Secondary to Spontaneous Pneumothorax after Esophageal Cancer Surgery: A Case Report. <i>Japanese Journal of Gastroenterological Surgery</i> , 2021, 54, 1-7.	0.1	0
17	The prognostic impact of peritoneal washing cytology for otherwise resectable extrahepatic cholangiocarcinoma patients. <i>Surgery Today</i> , 2021, 51, 1227-1231.	1.5	1
18	Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2871-2880.	1.7	5

#	ARTICLE	IF	CITATIONS
19	Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. <i>Pancreatology</i> , 2021, 21, 606-612.	1.1	4
20	High incidence of postoperative silent venous thromboembolism in ulcerative colitis: a retrospective observational study. <i>BMC Surgery</i> , 2021, 21, 247.	1.3	2
21	Coexisting Pancreatic Ductal Adenocarcinomas Derived from and Concomitant with Intraductal Papillary Mucinous Neoplasm in a Case with Pancreatic Divisum. <i>Japanese Journal of Gastroenterological Surgery</i> , 2021, 54, 408-415.	0.1	0
22	Utility of the inside stent as a preoperative biliary drainage method for patients with malignant perihilar biliary stricture. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 864-873.	2.6	8
23	Is surgery justified for elderly patients with extrahepatic cholangiocarcinoma? Reappraisal from a viewpoint of comorbidity and organ function. <i>Surgery Today</i> , 2021, 51, 1787-1794.	1.5	4
24	Falciform ligament hernia with specific abdominal symptom. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 566-569.	0.8	5
25	Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery. <i>Digestive Surgery</i> , 2021, 38, 352-360.	1.2	3
26	A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. <i>European Journal of Cancer</i> , 2021, 159, 215-223.	2.8	17
27	Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 64-74.	2.6	5
28	Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2020, 20, 1472-1478.	1.1	8
29	New surgical technique for pancreatic lithotripsy without coring-out. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 1343-1346.	0.8	0
30	Superior Mesenteric Artery Plexus-Preserving Pancreatoduodenectomy with Circumferential Dissection of Lymph Nodes. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1712-1719.	1.7	6
31	Flooring the Major Vessels with Falciform Ligament to Prevent Post-Pancreatectomy Hemorrhage. <i>World Journal of Surgery</i> , 2020, 44, 3478-3485.	1.6	7
32	Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 623-633.	1.9	1
33	Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 421-428.	2.6	0
34	Prognostic Significance of Lymph Node Metastasis and Micrometastasis Along the Left Side of Superior Mesenteric Artery in Pancreatic Head Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2100-2109.	1.7	12
35	Gastrectomy for invasive micropapillary carcinoma is associated with poorer disease-free and disease-specific survival. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1565-1573.	2.2	2
36	Usefulness of Amplatzer Vascular Plug for Preoperative Embolization Before Distal Pancreatectomy with En Bloc Celiac Axis Resection. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1352-1357.	2.0	4

#	ARTICLE	IF	CITATIONS
37	Decreased serum carbohydrate antigen 19â€“9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. <i>BMC Cancer</i> , 2019, 19, 252.	2.6	57
38	A Multicenter, Randomized, Controlled Trial Comparing Reinforced Staplers with Bare Staplers During Distal Pancreatectomy (HiSCO-07 Trial). <i>Annals of Surgical Oncology</i> , 2019, 26, 1519-1527.	1.5	39
39	Surgical Recurrence at Anastomotic Site After Bowel Resection in Crohnâ€™s Disease: Comparison of Kono-S and End-to-end Anastomosis. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 312-319.	1.7	51
40	Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19â€“9 is Highâ€“Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. <i>World Journal of Surgery</i> , 2019, 43, 634-641.	1.6	25
41	Strategy for the surgical treatment of non-functional pancreatic neuroendocrine tumors. <i>Suizo</i> , 2019, 34, 97-105.	0.1	1
42	Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1202-1210.	1.5	10
43	The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone. <i>Pancreatology</i> , 2018, 18, 191-197.	1.1	8
44	Prognostic impact of postoperative complication after pancreatoduodenectomy for pancreatic adenocarcinoma stratified by the resectability status. <i>Journal of Surgical Oncology</i> , 2018, 118, 1105-1114.	1.7	9
45	2î¼4ŽBRè†µç™CEã®è†â°Šç—...ç†â† çš,,ç%°1â³4 ä•ã®æ²»ç™,æ^†ç•¥. <i>Suizo</i> , 2018, 33, 18-26.	0.1	0
46	Impact of Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression on Prognosis After Surgical Resection for Biliary Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 990-999.	1.7	5
47	Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3â“Pancreatic Adenocarcinoma: Proposal for Reclassification of the Tumor Extending Beyond the Pancreas Based on Tumor Size. <i>World Journal of Surgery</i> , 2017, 41, 2867-2875.	1.6	5
48	A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 775-781.	2.3	22
49	Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 801-811.	2.3	14
50	Sarcopenia is closely associated with pancreatic exocrine insufficiency in patients with pancreatic disease. <i>Pancreatology</i> , 2017, 17, 70-75.	1.1	72
51	Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 393-398.	2.5	12
52	Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma. <i>Pancreatology</i> , 2017, 17, 95-102.	1.1	23
53	Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 37-47.	2.3	49
54	A case of mixed adeno-neuroendocrine carcinoma with liver metastasis of neuroendocrine tumor component after adjuvant chemotherapy: a case report and literature review. <i>Suizo</i> , 2017, 32, 752-759.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Preservation of pancreatic endocrine and exocrine function of patients who underwent pancreatic resection. <i>Suizo</i> , 2017, 32, 706-713.	0.1	3
56	Preoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-6.	1.5	32
57	Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 287-287.	2.8	4
58	Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016, 23, 188-197.	2.6	40
59	Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status. <i>Journal of Surgical Oncology</i> , 2016, 113, 405-412.	1.7	18
60	Nerve Growth Factor Expression Is Not Associated with Perineural Invasion in Extrahepatic Cholangiocarcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 774-784.	2.3	8
61	Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 115, 59-65.	6.4	133
62	Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. <i>Surgery</i> , 2016, 160, 293-305.	1.9	21
63	Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2019-2027.	1.5	33
64	Remnant pancreatic parenchymal volume predicts postoperative pancreatic exocrine insufficiency after pancreatectomy. <i>Surgery</i> , 2016, 159, 885-892.	1.9	41
65	Postpancreatoduodenectomy Hemorrhage Treated by Combined Transcatheter Arterial Embolization and Superior Mesenteric Artery to Iliac Artery Bypass: Report of a Case. <i>International Surgery</i> , 2015, 100, 1084-1088.	0.1	1
66	Reappraisal of Peritoneal Washing Cytology in 984 Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Margin-Negative Resection. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 6-14.	1.7	51
67	Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study. <i>Pancreatology</i> , 2015, 15, 674-680.	1.1	95
68	Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 1238-1246.	1.5	50
69	Arteriography after embolization before distal pancreatectomy with en bloc celiac axis resection. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2015, 24, 350-355.	1.2	11
70	Operative indication for serous cystic neoplasm of the pancreas. <i>Suizo</i> , 2015, 30, 585-591.	0.1	6
71	Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: Dosing considerations. <i>Pancreatology</i> , 2014, 14, 95-99.	1.1	3
72	Indicators for proper management of surgical drains following pancreaticoduodenectomy. <i>Journal of Surgical Oncology</i> , 2014, 109, 702-707.	1.7	17

#	ARTICLE	IF	CITATIONS
73	A Case of Pedunculated Duodenal GIST Growing Exophytically. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2014, 75, 2203-2209.	0.0	0
74	Perineural Invasion in Extrahepatic Cholangiocarcinoma: Prognostic Impact and Treatment Strategies. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 1429-1439.	1.7	44
75	Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma. <i>Journal of Surgical Oncology</i> , 2013, 107, 414-421.	1.7	50
76	Elevation of Urine Trypsinogen 2 Is an Independent Risk Factor for Pancreatic Fistula After Pancreaticoduodenectomy. <i>Pancreas</i> , 2012, 41, 876-881.	1.1	12
77	Combined Analysis of Dihydropyrimidine Dehydrogenase and Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Pancreatic Carcinoma Patients Treated with Adjuvant Gemcitabine Plus S-1 Chemotherapy after Surgical Resection. <i>Annals of Surgical Oncology</i> , 2012, 19, 646-655.	1.5	30
78	Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. <i>Journal of Surgical Oncology</i> , 2012, 106, 174-180.	1.7	35
79	Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 306-313.	2.6	28
80	Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 651-658.	1.5	210
81	Prognostic Impact of Para-aortic Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma. <i>World Journal of Surgery</i> , 2010, 34, 1900-1907.	1.6	63
82	Number of Metastatic Lymph Nodes, but Not Lymph Node Ratio, Is an Independent Prognostic Factor after Resection of Pancreatic Carcinoma. <i>Journal of the American College of Surgeons</i> , 2010, 211, 196-204.	0.5	140
83	Adjuvant Gemcitabine Plus S-1 Chemotherapy Improves Survival After Aggressive Surgical Resection for Advanced Biliary Carcinoma. <i>Annals of Surgery</i> , 2009, 250, 950-956.	4.2	107
84	Main pancreatic duct obstruction due to a small nonfunctioning endocrine tumor of the pancreas. <i>Hiroshima Journal of Medical Sciences</i> , 2009, 58, 45-8.	0.1	8
85	Combination of polyglycolic acid felt and fibrin glue for prevention of pancreatic fistula following pancreaticoduodenectomy. <i>Hepato-Gastroenterology</i> , 2009, 56, 1538-41.	0.5	10
86	A Soft Pancreatic Remnant is Associated with Increased Drain Fluid Pancreatic Amylase and Serum CRP Levels Following Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 51-56.	1.7	31
87	Reply to Comments on "An Antecolic Roux-en-Y Reconstruction Decreased Delayed Gastric Emptying After Pylorus-Preserving Pancreatoduodenectomy". <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1813-1814.	1.7	1
88	No mortality after 150 consecutive pancreatoduodenectomies with duct-to-mucosa pancreaticogastrostomy. <i>Journal of Surgical Oncology</i> , 2008, 97, 205-209.	1.7	61
89	Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy. <i>Journal of Surgical Oncology</i> , 2008, 98, 309-313.	1.7	38
90	Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. <i>American Journal of Surgery</i> , 2008, 195, 757-762.	1.8	49

#	ARTICLE	IF	CITATIONS
91	Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours. <i>Oncology Reports</i> , 2003, 10, 277-83.	2.6	31